{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T01:20:46Z","timestamp":1772500846969,"version":"3.50.1"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Natural Science Foundation of Zhejiang Province of China","award":["LR23F010002"],"award-info":[{"award-number":["LR23F010002"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62271178"],"award-info":[{"award-number":["62271178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U21A20521"],"award-info":[{"award-number":["U21A20521"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immunotherapy with immune checkpoint inhibitors (ICIs) is increasingly used to treat various tumor types. Determining patient responses to ICIs presents a significant clinical challenge. Although components of the tumor microenvironment (TME) are used to predict patient outcomes, comprehensive assessments of the TME are frequently overlooked. Using a top-down approach, the TME was divided into five layers\u2014outcome, immune role, cell, cellular component, and gene. Using this structure, a neural network called TME-NET was developed to predict responses to ICIs. Model parameter weights and cell ablation studies were used to investigate the influence of TME components. The model was developed and evaluated using a pan-cancer cohort of 948 patients across four cancer types, with Area Under the Curve (AUC) and accuracy as performance metrics. Results show that TME-NET surpasses established models such as support vector machine and k-nearest neighbors in AUC and accuracy. Visualization of model parameter weights showed that at the cellular layer, Th1 cells enhance immune responses, whereas myeloid-derived suppressor cells and M2 macrophages show strong immunosuppressive effects. Cell ablation studies further confirmed the impact of these cells. At the gene layer, the transcription factors STAT4 in Th1 cells and IRF4 in M2 macrophages significantly affect TME dynamics. Additionally, the cytokine-encoding genes IFNG from Th1 cells and ARG1 from M2 macrophages are crucial for modulating immune responses within the TME. Survival data from immunotherapy cohorts confirmed the prognostic ability of these markers, with p-values &amp;lt;0.01. In summary, TME-NET performs well in predicting immunotherapy responses and offers interpretable insights into the immunotherapy process. It can be customized at https:\/\/immbal.shinyapps.io\/TME-NET.<\/jats:p>","DOI":"10.1093\/bib\/bbae410","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T03:14:29Z","timestamp":1724296469000},"source":"Crossref","is-referenced-by-count":4,"title":["TME-NET: an interpretable deep neural network for predicting pan-cancer immune checkpoint inhibitor responses"],"prefix":"10.1093","volume":"25","author":[{"given":"Xiaobao","family":"Ding","sequence":"first","affiliation":[{"name":"Institute of Biomedical Engineering and Instrumentation, Hangzhou Dianzi University , Hangzhou 310018, Zhejiang , China"},{"name":"Institute of Big Data and Artificial Intelligence in Medicine, School of Electronics and Information Engineering, Taizhou University , Taizhou 318000, Zhejiang , China"},{"name":"School of Computer Science and Technology, Hangzhou Dianzi University , Hangzhou, 310018 , China"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering and Instrumentation, Hangzhou Dianzi University , Hangzhou 310018, Zhejiang , China"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5626-7076","authenticated-orcid":false,"given":"Ming","family":"Fan","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering and Instrumentation, Hangzhou Dianzi University , Hangzhou 310018, Zhejiang , China"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0435-6453","authenticated-orcid":false,"given":"Lihua","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering and Instrumentation, Hangzhou Dianzi University , Hangzhou 310018, Zhejiang , China"},{"name":"School of Computer Science and Technology, Hangzhou Dianzi University , Hangzhou, 310018 , China"}]}],"member":"286","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"2024082200564628800_ref1","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma","volume":"24","author":"Gide","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2024082200564628800_ref2","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1101\/gr.191098.115","article-title":"The first five years of single-cell cancer genomics and beyond","volume":"25","author":"Navin","year":"2015","journal-title":"Genome Res"},{"key":"2024082200564628800_ref3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2024082200564628800_ref4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2024082200564628800_ref5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40364-020-00209-0","article-title":"Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors","volume":"8","author":"Bai","year":"2020","journal-title":"Biomark Res"},{"key":"2024082200564628800_ref6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"2024082200564628800_ref7","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/s41416-022-01743-4","article-title":"Biomarkers of response to PD-1 pathway blockade","volume":"126","author":"Li","year":"2022","journal-title":"Br J Cancer"},{"key":"2024082200564628800_ref8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","article-title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2024082200564628800_ref9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"Jci Insight"},{"key":"2024082200564628800_ref10","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2024082200564628800_ref11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"2024082200564628800_ref12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2024082200564628800_ref13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/1078-0432.CCR-22-0015","article-title":"Microenvironment is a key determinant of immune checkpoint inhibitor response","volume":"28","author":"Cho","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2024082200564628800_ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s43152-023-00052-z","article-title":"Tumor microenvironment regulates immune checkpoints: emerging need of combinatorial therapies","volume":"5","author":"Kalia","year":"2024","journal-title":"Current Tissue Microenvironment Reports"},{"key":"2024082200564628800_ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.021","article-title":"Immune checkpoints in the tumor microenvironment","volume":"65","author":"Toor","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"2024082200564628800_ref16","first-page":"1","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"key":"2024082200564628800_ref17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41467-017-02391-6","article-title":"Perturbation-response genes reveal signaling footprints in cancer gene expression","volume":"9","author":"Schubert","year":"2018","journal-title":"Nat Commun"},{"key":"2024082200564628800_ref18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2019.194431","article-title":"Transfer of regulatory knowledge from human to mouse for functional genomics analysis","volume":"1863","author":"Holland","year":"2020","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"2024082200564628800_ref19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41592-019-0690-6","article-title":"Benchmarking algorithms for gene regulatory network inference from single-cell transcriptomic data","volume":"17","author":"Pratapa","year":"2020","journal-title":"Nat Methods"},{"key":"2024082200564628800_ref20","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1038\/ncomms8866","article-title":"A draft network of ligand-receptor-mediated multicellular signalling in human","volume":"6","author":"Ramilowski","year":"2015","journal-title":"Nat Commun"},{"key":"2024082200564628800_ref21","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac234","article-title":"Cell-cell communication inference and analysis in the tumour microenvironments from single-cell transcriptomics: data resources and computational strategies","volume":"23","author":"Peng","year":"2022","journal-title":"Brief Bioinform"},{"key":"2024082200564628800_ref22","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102742","article-title":"TimiGP: an R package to depict the tumor microenvironment from bulk transcriptomics","volume":"4","author":"Li","year":"2023","journal-title":"STAR Protoc"},{"key":"2024082200564628800_ref23","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1038\/s41467-022-31535-6","article-title":"Network-based machine learning approach to predict immunotherapy response in cancer patients","volume":"13","author":"Kong","year":"2022","journal-title":"Nat Commun"},{"key":"2024082200564628800_ref24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41467-021-27651-4","article-title":"Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association","volume":"13","author":"Wu","year":"2022","journal-title":"Nat Commun"},{"key":"2024082200564628800_ref25","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104228","article-title":"Deep neural network modeling identifies biomarkers of response to immune-checkpoint therapy","volume":"25","author":"Kang","year":"2022","journal-title":"Iscience"},{"key":"2024082200564628800_ref26","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-021-03922-4","article-title":"Biologically informed deep neural network for prostate cancer discovery","volume":"598","author":"Elmarakeby","year":"2021","journal-title":"Nature"},{"key":"2024082200564628800_ref27","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/s12859-018-2500-z","article-title":"PASNet: pathway-associated sparse deep neural network for prognosis prediction from high-throughput data","volume":"19","author":"Hao","year":"2018","journal-title":"Bmc Bioinformatics"},{"key":"2024082200564628800_ref28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nmeth.4627","article-title":"Using deep learning to model the hierarchical structure and function of a cell","volume":"15","author":"Ma","year":"2018","journal-title":"Nat Methods"},{"key":"2024082200564628800_ref29","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ccell.2020.09.014","article-title":"Predicting drug response and synergy using a deep learning model of human cancer cells","volume":"38","author":"Kuenzi","year":"2020","journal-title":"Cancer Cell"},{"key":"2024082200564628800_ref30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s42003-021-02622-z","article-title":"GenNet framework: interpretable deep learning for predicting phenotypes from genetic data","volume":"4","author":"Hilten","year":"2021","journal-title":"Commun Biol"},{"key":"2024082200564628800_ref31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104452","article-title":"An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers","volume":"88","author":"Mezheyeuski","year":"2023","journal-title":"EBioMedicine"},{"key":"2024082200564628800_ref32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.tcb.2014.11.001","article-title":"Balancing the innate immune system in tumor development","volume":"25","author":"Hagerling","year":"2015","journal-title":"Trends Cell Biol"},{"key":"2024082200564628800_ref33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7554\/eLife.62420","article-title":"The effects of age and systemic metabolism on anti-tumor T cell responses","volume":"9","author":"Drijvers","year":"2020","journal-title":"Elife"},{"key":"2024082200564628800_ref34","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102533","article-title":"Extracellular vesicles (exosomes) as immunosuppressive mediating variables in tumor and chronic inflammatory microenvironments","volume":"10","author":"Awadasseid","year":"2021","journal-title":"Cells"},{"key":"2024082200564628800_ref35","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"key":"2024082200564628800_ref36","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"2024082200564628800_ref37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"2024082200564628800_ref38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"2024082200564628800_ref39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"2024082200564628800_ref40","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2017.35.15_suppl.4505","article-title":"IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun)","volume":"35","author":"Atkins","year":"2017","journal-title":"American Society of Clinical Oncology"},{"key":"2024082200564628800_ref41","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"key":"2024082200564628800_ref42","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","article-title":"Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma","volume":"22","author":"Choueiri","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2024082200564628800_ref43","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"2024082200564628800_ref44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"The Lancet"},{"key":"2024082200564628800_ref45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"key":"2024082200564628800_ref46","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"key":"2024082200564628800_ref47","author":"Invitrogen Immune Cell Guide"},{"key":"2024082200564628800_ref48","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2024082200564628800_ref49","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: markers, development, states, and unaddressed complexity","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"key":"2024082200564628800_ref50"},{"key":"2024082200564628800_ref51"},{"key":"2024082200564628800_ref52"},{"key":"2024082200564628800_ref53"},{"key":"2024082200564628800_ref54","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10462-021-10033-z","article-title":"A review on weight initialization strategies for neural networks","volume":"55","author":"Narkhede","year":"2022","journal-title":"Artificial Intelligence Review"},{"key":"2024082200564628800_ref55","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1109\/TII.2012.2187914","article-title":"Selection of proper neural network sizes and architectures\u2014a comparative study","volume":"8","author":"Hunter","year":"2012","journal-title":"IEEE Trans Industr Inform"},{"key":"2024082200564628800_ref56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.669474","article-title":"Differentiation and regulation of TH cells: a balancing act for cancer immunotherapy","volume":"12","author":"Basu","year":"2021","journal-title":"Front Immunol"},{"key":"2024082200564628800_ref57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-030-35723-8_8","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment","volume":"1224","author":"Dysthe","year":"2020","journal-title":"Tumor Microenvironment: Hematopoietic Cells\u2013Part A"},{"key":"2024082200564628800_ref58","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci"},{"key":"2024082200564628800_ref59","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/s12967-022-03807-8","article-title":"Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer","volume":"20","author":"Chen","year":"2022","journal-title":"J Transl Med"},{"key":"2024082200564628800_ref60","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.4049\/jimmunol.169.8.4388","article-title":"Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R beta 2 chain expression and signaling","volume":"169","author":"Nishikomori","year":"2002","journal-title":"J Immunol"},{"key":"2024082200564628800_ref61","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/ni.1920","article-title":"The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection","volume":"11","author":"Satoh","year":"2010","journal-title":"Nat Immunol"},{"key":"2024082200564628800_ref62","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.7150\/thno.26888","article-title":"Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages","volume":"8","author":"Arlauckas","year":"2018","journal-title":"Theranostics"},{"key":"2024082200564628800_ref63","doi-asserted-by":"crossref","first-page":"iyad031","DOI":"10.1093\/genetics\/iyad031","article-title":"The Gene Ontology knowledgebase in 2023","volume":"224","author":"Gene Ontology","year":"2023","journal-title":"Genetics"},{"key":"2024082200564628800_ref64","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13578-018-0232-4","article-title":"Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1\/PD-L1 blockade mediated cancer immunotherapy?","volume":"8","author":"Tang","year":"2018","journal-title":"Cell Biosci"},{"key":"2024082200564628800_ref65","doi-asserted-by":"crossref","first-page":"155247","DOI":"10.1016\/j.cyto.2020.155247","article-title":"Th1 concomitant immune response mediated by IFN-gamma protects against sand fly delivered Leishmania infection: implications for vaccine design","volume":"147","author":"Seyed","year":"2021","journal-title":"Cytokine"},{"key":"2024082200564628800_ref66","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082150","article-title":"The perfect combination: enhancing patient response to PD-1-based therapies in epithelial ovarian cancer","volume":"12","author":"James","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2024082200564628800_ref67","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.apsb.2021.03.027","article-title":"Role of CD8(+) T lymphocyte cells: interplay with stromal cells in tumor microenvironment","volume":"11","author":"Xie","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"2024082200564628800_ref68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2024082200564628800_ref69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-gamma in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark Res"},{"key":"2024082200564628800_ref70","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12885-024-12101-3","article-title":"Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes","volume":"24","author":"Fang","year":"2024","journal-title":"BMC Cancer"},{"key":"2024082200564628800_ref71","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41592-021-01102-w","article-title":"User-friendly, scalable tools and workflows for single-cell RNA-seq analysis","volume":"18","author":"Moreno","year":"2021","journal-title":"Nat Methods"},{"key":"2024082200564628800_ref72","doi-asserted-by":"crossref","first-page":"D129","DOI":"10.1093\/nar\/gkab1030","article-title":"Expression atlas update: gene and protein expression in multiple species","volume":"50","author":"Moreno","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2024082200564628800_ref73","doi-asserted-by":"crossref","first-page":"D1425","DOI":"10.1093\/nar\/gkac959","article-title":"TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment","volume":"51","author":"Han","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2024082200564628800_ref74","doi-asserted-by":"crossref","first-page":"D1420","DOI":"10.1093\/nar\/gkaa1020","article-title":"TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment","volume":"49","author":"Sun","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"2024082200564628800_ref75","article-title":"Single cell portal: an interactive home for single-cell genomics data","author":"Tarhan","year":"2023","journal-title":"bioRxiv"},{"key":"2024082200564628800_ref76","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2018.15","article-title":"ImmPort, toward repurposing of open access immunological assay data for translational and clinical research","volume":"5","author":"Bhattacharya","year":"2018","journal-title":"Sci Data"},{"key":"2024082200564628800_ref77","doi-asserted-by":"crossref","first-page":"D870","DOI":"10.1093\/nar\/gkac947","article-title":"CellMarker 2.0: an updated database of manually curated cell markers in human\/mouse and web tools based on scRNA-seq data","volume":"51","author":"Hu","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2024082200564628800_ref78","doi-asserted-by":"crossref","first-page":"D523","DOI":"10.1093\/nar\/gkac1052","article-title":"UniProt: the universal protein knowledgebase in 2023","volume":"51","author":"UniProt","year":"2023","journal-title":"Nucleic Acids Res"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/25\/5\/bbae410\/58879723\/bbae410.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/25\/5\/bbae410\/58879723\/bbae410.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T03:15:20Z","timestamp":1724296520000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbae410\/7738055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbae410","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,25]]},"article-number":"bbae410"}}